Barcelona, Aug 16 (EFE).- Hospitals in Catalonia started Monday selecting volunteers to take part in the first round of clinical trials for the Covid-19 vaccine developed by Spanish pharmaceutical company Hipra.
The Spanish Agency of Medicines and Medical Devices authorized Hipra to begin human clinical trials of their vaccine on August 11.
In this first phase, dozens of volunteers between the ages of 18 and 39 who have not been infected by the coronavirus nor vaccinated against it are recruited.
The eligible volunteers will be inoculated with two doses of the vaccine 21 days apart to test the drug’s safety, tolerance and efficacy.
“HIPRA SARS-CoV-2, is a recombinant protein vaccine that has been designed to optimize its safety and induce a potent immune response that neutralizes the Covid-19 virus,” the company said in a statement.
The pharmaceutical company, with manufacturing plants in Spain and Brazil, said it planned to produce 400 million doses during 2022 and reach up to 1.2 billion doses by 2023. EFE